Breaking Down the First “Breakthrough”
This article was originally published in RPM Report
Vertex’ cystic fibrosis research is the recipient of the first two “Breakthrough” designations issued by FDA. That underscores the likelihood that the primary value of the new pathway will be as a badge for investors. And that’s probably a good thing.
You may also be interested in...
Drug sponsors are eager to use FDA’s new “breakthrough” therapy development pathway, and the agency is granting designations at a much faster rate than originally expected. But the “all hands on deck” approach required by FDA officials for breakthrough is resource-intensive at a time when the budget sequestration is preventing the agency from accessing all its available user fee funding. Is the popular program at risk?
CDER Director Janet Woodcock is ready to declare victory for personalized medicine reaching the mainstream. That means it is time to move onto new challenges in drug development, such as inter-company collaboration.
The Prescription Drug User Fee Act reauthorization made a number of important changes to the new drug review process and programs for stakeholder engagement with FDA. It also created a number of new investor communication challenges for sponsors.